Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Our new ERP system will be able to provide us with the right data-driven visibility to run the business in a more efficient and cost effective manner |
| Accuray technology is uniquely positioned to deliver stereotactic radiosurgery and SBRT and is driving preference at top cancer centers around the world |
| We are making great progress toward our fiscal year 2024 priorities, which include achieving above market revenue growth through new product innovation and commercial execution; expanding margins and profitability through enhanced pricing and operating efficiencies; and competing more effectively by leveraging strategic partnerships in new product development and market access |
| So we're really excited about its ability to make a difference in patient care, but also differentiate the Radixact platform |
| So we take that as a very positive sign |
| During the quarter, we grew global revenue by 8% year-over-year with product revenue growing 17% year-over-year, demonstrating better than expected customer demand in our first quarter versus the same period last year |
| And we showed it for the first time in some private demos at the ASTRO conference, and I will tell you that the feedback was excellent |
| Order backlog at $489 million is robust, representing greater than 2x fiscal year 2023 product revenue |
| Despite these expected challenges and learning how to navigate a brand new ERP environment, the teams worked around the clock to ensure a successful implementation, which we are all very proud of |
| And we see that as a positive thing for our technology |
| hospitals are not losing money by going to a more advanced care, which is the, again, the shorter duration treatments, which is better for the patient, better for the healthcare system overall |
| We think we'll have the opportunity to get great market traction as well as gain market share in the Type B space |
| Finally, new order growth was also solid, outpacing product revenue shipments |
| While we don't guide on orders, we are very pleased to deliver to our 1.2 book to bill target |
| We see this as a strong metric to gauge future growth and grow our backlog |
| We were able to drive tremendous interest in our new product innovations designed to advance care in a premium segment of the market |
| And so we believe the demand for the product is going to be strong |
| But I mean overall, we feel very good about our performance and the new products that we have introduced at ASTRO, the customer response and the momentum, as well as what we are seeing operationally in terms of our margin improvement |
| I mean, very strong results this quarter, but you're holding guidance -- it's 1 quarter into the fiscal year |
| Finally, we have an incredible leadership team in place that I believe is second to none in the industry |
| We are now offering the broadest and most innovative product portfolio in our company's history and are poised to capitalize on promising clinical trends and opportunities in the competitive landscape |
| I'm very pleased with our Q1 results and our strong start to the year |
| As Suzanne mentioned, we believe the book to bill ratio is the right metric to ensure healthy growth for our backlog and is also a good indicator of future business vitality |
| We believe that our comprehensive adaptive tool set, including Cenos, will be a key differentiator for Accuray Radixact versus competitive products and expect it to further increase our win rates and momentum for upgrading the aged TomoTherapy installed base |
| radiation oncology community, it was clear there was a positive outlook, backed by technology developments and emerging clinical data that demonstrate the curative impact of high precision, personalized radiation therapy |
| This gives us confidence that the long-term future for radiation oncology is very strong, despite some short-term headwinds due to the higher installation costs and longer cycles that have delayed some projects in the U.S |
| The Accuray team had a strong start to the fiscal year, delivering on both revenue and EBITDA in the quarter |
| This gives us confidence in our ability to deliver on our strategic goals of faster growth in the market and gaining share this fiscal year and beyond |
| We will be leveraging their leadership experience to further position the company to win and gain share through innovation and unparalleled service and support |
| This approval unlocks the ability for our China team to drive orders and build backlog in the Type B market segment, which represents approximately $600 million in annual market opportunity |
| Statement |
|---|
| Finally, we had 4 order cancellations of $9 million in the quarter, all coming from the Japan region due to a termination of a distributor, which we expect to win back through our existing distributors in the coming quarters |
| Service revenue for the quarter was $51 million, down 1% from the prior year and down 1% on a constant currency basis with an increase in contract revenue being offset by lower installation, training and spare parts revenue, which we expect to bounce back in Q2 |
| U.S., I think as we talked about here, there was some slowing and some extended sales cycles |
| This reported backlog is 9% lower than prior year due to 14 orders representing $31 million that aged beyond 30 months, which we do not include in our report backlog |
| Our net inventory balance was $150 million, up $5 million from the prior quarter due to lower shipments in Q1 |
| I think that being said, we did see about a $2.5 million headwind related to inflation that hit our P&L this particular quarter |
| Operating income for the quarter was $2.2 million compared to an operating loss of $2.2 million from the prior year |
| I would like to begin by thanking our global employees and cross-functional teams who executed with dedication to deliver a solid first quarter while also undergoing a full-scale ERP implementation, which presented quite a few operational and reporting challenges as part of the go-live and data migration process |
| So it's certainly not eased up for us |
| I would tell you in general, in terms of inflation, we're certainly seeing that the supplier price increases have slowed down |
| I just wanted to understand, I guess, the level of conservatism embedded in that guidance reiteration |
| Our overall gross margin for the quarter was 38% compared to 35.9% in the prior year, primarily due to lower parts consumption and associated freight expenses versus last year |
Please consider a small donation if you think this website provides you with relevant information